HeartSciences shares surge 11.07% premarket after launching MyoVista Insights 1.1 with AI-enhanced ECG features and expanded interoperability.

HeartSciences surged 11.07% in premarket trading following the commercial launch of MyoVista Insights version 1.1, a cloud-native ECG management platform with enhanced usability, AI-enabled workflow tools, and expanded interoperability across devices and file formats. The update aims to streamline clinical interpretation, reduce operational costs, and improve cardiac care efficiency, with the CEO highlighting strong early adopter validation and ongoing commercial discussions with major healthcare institutions. The platform’s vendor-agnostic design and focus on actionable insights position it as a competitive solution in ECG technology, reinforcing the company’s growth trajectory.